+------------------------------------------------------------------------------+
MORE: AstraZeneca 2014 Forecast Worse Than Estimated by Analysts 2014-02-06 07:25:21.862 GMT
By Sheela Sharma Feb. 6 (Bloomberg) -- AstraZeneca 2014 core EPS est. $4.52 vs 2013 core EPS $5.05; implies 10.5% core EPS decline in 2014: Bloomberg Data. * 2014 rev. est. $25.41b vs 2013 rev. $25.71b; implies rev. decline of 1.2% in 2014: Bloomberg data * Today: AstraZeneca sees 2014 core EPS decline in teens, low- to-mid single digit percentage decline in rev. at constant FX * CEO Pascal Soriot says in statement, financial performance for 2013 reflects ongoing impact from loss of exclusivity for several key brands * Headwinds will remain challenging in near term, confident of return to growth faster than anticipated; 2017 revenues seen broadly in line with 2013 * NOTE: Jan. 14, AstraZeneca Sees 2017 Rev. Broadly In-Line With 2013 * Conf. call at 12pm GMT on +44-(0)1452-557-749, pw 29599313 Statement
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editor: Sheela Sharma
To contact the reporter on this story: Sheela Sharma in London at +44-20-7392-0395 or ssharma145@bloomberg.net
To contact the editor responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net